Reproductive Health Matters
Volume 13, Issue 26 , Pages 84-92 , November 2005

Reaching Women with Instructions on Misoprostol Use in a Latin American Country

References 

  1. Wulf D, Singh S. An Overview of Clandestine Abortion in Latin America. New York: Alan Guttmacher Institute; 1996;At: 〈 www.guttmacher.org/pubs/ib12.html〉. Accessed 18 May 2005
  2. World Health Organization. Unsafe abortion: global and regional estimates of the incidence of unsafe abortion and associated mortality in 2000. 4th ed. Geneva: WHO; 2004;At: 〈 www.who.int/reproductive-health/unsafe_abortion/〉. Accessed 12 August 2005
  3. Chong YS, Su LL, Arulkumaran S. Misoprostol: a quarter century of use, abuse, and creative misuse. Obstetrical and Gynecological Survey. 2004;59(2):128–140
  4. Lokugamage AU, El Refaey H, Rodeck CH. Misoprostol and pregnancy: ever-increasing indications of effective usage. Current Opinion in Obstetrics and Gynecology. 2003;15(6):513–518
  5. Burns M. Misoprostol use in obstetrics and gynecology. Outlook. 2005;21(4):1–8
  6. Clark S, Blum J, Blanchard K, et al. Misoprostol use in obstetrics and gynecology in Brazil, Jamaica, and the United States. International Journal of Gynecology and Obstetrics. 2002;76(1):65–74
  7. Ashok PW, Penney GC, Flett GMM, et al. An effective regimen for early medical abortion: a report of 2000 consecutive cases. Human Reproduction. 1998;13(10):2962–2965
  8. Schaff EA, Fielding SL, Westhoff C, et al. Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: a randomized trial. Journal of the American Medical Association. 2000;284:1948–1953
  9. In:  Abuabara K,  Blue J editor. Providing medical abortion in developing countries: an introductory guidebook. Results of a team residency at the Bellagio Study and Conference Center. New York: Gynuity Health Projects; 2004;
  10. Carbonell JL, Varela L, Velazco A, et al. The use of misoprostol for abortion at less than or equal to 9 weeks' gestation. European Journal of Contraception and Reproductive Health Care. 1997;2(3):181–185
  11. Jain JK, Meckstroth KR, Michell DR. Early pregnancy termination with intravaginally administered sodium chloride solution-moistened misoprostol tablets: historical comparison with mifepristone and oral misoprostol. American Journal of Obstetrics and Gynecology. 1999;181(6):1386–1391
  12. Carbonell JL, Rodriguez J, Aragon S, et al. Vaginal misoprostol 1000 micrograms for early abortion. Contraception. 2001;63(3):131–136
  13. Jain JK, Harwood B, Meckstroth KR, et al. Early pregnancy termination with vaginal misoprostol combined with loperamide and acetaminophen prophylaxis. Contraception. 2001;63(4):217–221
  14. Jain JK, Dutton C, Harwood B, et al. A prospective randomized, double-blinded, placebo-controlled trial comparing mifepristone and vaginal misoprostol to vaginal misoprostol alone for elective termination of pregnancy. Human Reproduction. 2002;17(6):1477–1482
  15. Billings D. Misoprostol alone for early medical abortion in a Latin American clinic setting. Reproductive Health Matters. 2004;12(24 Suppl):57–64
  16. Sherris J, Bingham A, Burns MA, et al. Misoprostol use in developing countries: results from a multicountry study. International Journal of Gynecology and Obstetrics. 2005;88(1):76–81
  17. Pollack AE, Pine RN. Opening a door to safe abortion: international perspectives on medical abortifacient use. Journal of American Medical Women's Association. 2000;55(3 Suppl):186–188
  18. Blanchard K, Clark S, Winikoff B, et al. Misoprostol for women's health: a review. Obstetrics and Gynecology. 2002;99(2):316–332
  19. Lafaurie MM, Grossman D, Troncoso E, et al. Women's perspectives on medical abortion: an exploratory, qualitative study in Mexico, Colombia, Ecuador and Peru. Reproductive Health Matters. 2005;13(26):75–83
  20. Philip NM, Winikoff B, Moore K, et al. A consensus regimen for early abortion with misoprostol. International Journal of Gynecology and Obstetrics. 2004;87(3):281–283
  21. Faria VE. Government policy and fertility regulation: unintended consequences and perverse effects. Brazilian Journal of Population Studies. 1997;1:1–29
  22. Belizan JM, Althabe F, Barros FC, et al. Rates and implications of caesarean sections in Latin America: ecological study. British Medical Journal. 1999;319:1397–1400
  23. Castro A. Commentary: increase in caesarean sections may reflect medical control not women's choice. British Medical Journal. 1999;319:1401–1402
  24. Silva M. Physicians and abortion: a study of the willingness to provide legal abortion due to rape in Mexico. PhD dissertation (defended 6 September 2005). Tulane University, Department of International Health and Development, New Orleans, LA.
  25. Torres Escobar I. Actitud de los médicos tratantes de los abortos que se presentan en los hospitales del Distrito federal. GIRE: Investigación preparada para Population Council/Ipas. México. 1993;
  26. Jenkins GL. Burning bridges: policy, practice, and the destruction of midwifery in rural Costa Rica. Social Science & Medicine. 2003;56(9):1893–1909
  27. Aguilar SE, Ortiz O. Preprueba del tríptico informativo: aborto médico temprano con misoprostol. Unpublished report to Ipas. 2004;
  28. Consensus Statement: Instructions for use – Abortion induction with misoprostol in pregnancies through nine weeks LMP. Expert meeting on misoprostol. Reproductive Health Technologies Project, Gynuity Health Projects. Washington DC, 28 July 2003.
  29. Blanchard K, Shochet T, Coyaji K, et al. Misoprostol alone for early abortion: an evaluation of seven potential regimens. Contraception. 2005;72(2):91–97
  30. Gould H, Ellertson C, Corona G. Knowledge and attitudes about the differences between emergency contraception and medical abortion among middle-class women and men of reproductive age in Mexico City. Contraception. 2002;66(6):417–426
  31. McNaughton HL, Mitchell EMH, Blandon MM. Should doctors be the judges? Ambiguous policies on legal abortion in Nicaragua. Reproductive Health Matters. 2004;12(24 Suppl):18–26
  32. Althaus FA. Work in progress: the expansion of access to abortion services in South Africa following legalization. International Family Planning Perspectives. 2000;26(2):84–86
  33. Ipas, IHCAR. Deciding women's lives are worth saving: expanding the role of midlevel providers in safe abortion care. Issues in Abortion Care 7. Ipas: Chapel Hill; 2002;
  34. Beitz J. Increasing access to reproductive health services through pharmacists. Outlook. 2004;21(2):1–8
  35. Lara D, Abuabara K, Grossman D, et al. Pharmacist provision of medical abortifacients in Mexico City. Abstract presented at American Public Health Association Annual Meeting, Washington DC, 8 November 2004.

PII: S0968-8080(05)26202-X

doi: 10.1016/S0968-8080(05)26202-X

Reproductive Health Matters
Volume 13, Issue 26 , Pages 84-92 , November 2005

Article Tools

* Image Usage & Resolution